INMUNE BIO INC. Revenue
INMUNE BIO INC. (INMB) reported Revenue of $50.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-30.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-08-06
- INMUNE BIO INC. revenues for the quarter ending 2025-12-31 was $0.00.
- INMUNE BIO INC. revenues for the quarter ending 2025-09-30 was $0.00.
- INMUNE BIO INC. revenues for the quarter ending 2025-06-30 was $0.00.
- INMUNE BIO INC. revenues for the quarter ending 2025-03-31 was $50.00K, a 257.14% increase year-over-year.
- INMUNE BIO INC. revenues for fiscal 2025 was $50.00K, a 257.14% increase from fiscal 2024.
- INMUNE BIO INC. revenues for fiscal 2024 was $14.00K, a 90.97% decline from fiscal 2023.
- INMUNE BIO INC. revenues for fiscal 2023 was $155.00K, a 58.56% decline from fiscal 2022.
- INMUNE BIO INC. revenues for fiscal 2022 was $374.00K, a 106.63% increase from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 derived: sum of 3 quarters · filed 2026-08-06 | $50.00K 10-K · filed 2026-03-30 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2026-08-06 | $50.00K 10-Q · filed 2025-10-30 | $50.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $50.00K 10-Q · filed 2026-08-06 | $50.00K derived: sum of 3 quarters · filed 2026-08-06 | $50.00K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $50.00K 10-Q · filed 2026-05-07 | $50.00K derived: sum of 2 quarters · filed 2026-05-07 | $50.00K derived: sum of 3 quarters · filed 2026-05-07 | $50.00K derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $0.00 derived: sum of 2 quarters · filed 2026-03-30 | $0.00 derived: sum of 3 quarters · filed 2026-03-30 | $14.00K 10-K · filed 2026-03-30 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $0.00 derived: sum of 2 quarters · filed 2025-10-30 | $14.00K 10-Q · filed 2025-10-30 | $42.00K derived: sum of 4 quarters · filed 2025-10-30 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $14.00K 10-Q · filed 2025-08-07 | $42.00K derived: sum of 3 quarters · filed 2025-08-07 | $85.00K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $14.00K 10-Q · filed 2025-05-08 | $42.00K derived: sum of 2 quarters · filed 2025-05-08 | $85.00K derived: sum of 3 quarters · filed 2025-05-08 | $131.00K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $71.00K derived: sum of 2 quarters · filed 2025-03-27 | $117.00K derived: sum of 3 quarters · filed 2025-03-27 | $155.00K 10-K · filed 2025-03-27 | |
| 2023-09-30 | $43.00K 10-Q · filed 2024-10-31 | $89.00K derived: sum of 2 quarters · filed 2024-10-31 | $127.00K 10-Q · filed 2024-10-31 | $224.00K derived: sum of 4 quarters · filed 2024-10-31 | |
| 2023-06-30 | $46.00K 10-Q · filed 2024-08-01 | $84.00K 10-Q · filed 2024-08-01 | $181.00K derived: sum of 3 quarters · filed 2024-08-01 | $279.00K derived: sum of 4 quarters · filed 2024-08-01 | |
| 2023-03-31 | $38.00K 10-Q · filed 2024-05-09 | $135.00K derived: sum of 2 quarters · filed 2024-05-09 | $233.00K derived: sum of 3 quarters · filed 2024-05-09 | $249.00K derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $97.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $195.00K derived: sum of 2 quarters · filed 2024-03-28 | $211.00K derived: sum of 3 quarters · filed 2024-03-28 | $374.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $98.00K 10-Q · filed 2023-11-01 | $114.00K derived: sum of 2 quarters · filed 2023-11-01 | $277.00K 10-Q · filed 2023-11-01 | $440.00K derived: sum of 4 quarters · filed 2023-11-01 | |
| 2022-06-30 | $16.00K 10-Q · filed 2023-08-07 | $179.00K 10-Q · filed 2023-08-07 | $342.00K derived: sum of 3 quarters · filed 2023-08-07 | $356.00K derived: sum of 4 quarters · filed 2023-08-07 | |
| 2022-03-31 | $163.00K 10-Q · filed 2023-05-03 | $326.00K derived: sum of 2 quarters · filed 2023-05-03 | $340.00K derived: sum of 3 quarters · filed 2023-05-03 | $340.00K derived: sum of 4 quarters · filed 2023-05-03 | |
| 2021-12-31 | $163.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $177.00K derived: sum of 2 quarters · filed 2023-03-02 | $177.00K derived: sum of 3 quarters · filed 2023-03-02 | $181.00K 10-K · filed 2023-03-02 | |
| 2021-09-30 | $14.00K 10-Q · filed 2022-11-02 | $14.00K derived: sum of 2 quarters · filed 2022-11-02 | $18.00K 10-Q · filed 2022-11-02 | ||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $4.00K 10-Q · filed 2022-08-03 | |||
| 2021-03-31 | $4.00K 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | $11.00K 10-K · filed 2022-03-03 | $10.92K 10-K · filed 2021-03-04 | |||
| 2019-06-30 | $0.00 10-Q · filed 2019-08-09 | $0.00 10-Q · filed 2019-08-09 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-15 | ||||
| 2018-12-31 | $0.00 10-K · filed 2019-03-29 | ||||
| 2018-06-30 | $0.00 10-Q · filed 2019-08-09 | $0.00 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-15 | ||||
| 2017-12-31 | $0.00 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |